Utah Medicaid and Wegovy or Zepbound After the Weight-Loss Pilot Ended

Not for weight loss anymore. Utah Medicaid paid for Wegovy, Zepbound and Saxenda for obesity through a legislative pilot, and its May 2026 provider bulletin said fee-for-service coverage for weight loss would end June 30, 2026.^[10] Its prior authorization form limits those approvals to that date and takes no new starts.^[1] As of November 2026 adults can still get Wegovy for heart disease or MASH and Zepbound for sleep apnea, and diabetes GLP-1s need only a diagnosis code.^[1][2]

Can you still get Wegovy or Zepbound for weight loss on Utah Medicaid?

No new approvals are possible on the current form, posted June 19, 2026.^[3] The obesity box on page one now leads only to a reauthorization section, and that section asks whether the patient already had a weight-loss approval active between July 1, 2025 and June 30, 2026.^[1] The prescriber must also acknowledge that this coverage came from a pilot set up by the legislature, one the state warned might stop after June 30, 2026, and the form’s duration table caps those reauthorizations at that date.^[1] The state’s May 2026 bulletin settled the question: effective June 30, 2026, fee-for-service Medicaid “will no longer cover GLP-1 agonists, including Wegovy, Saxenda, and Zepbound for weight loss,” while coverage for heart, liver and sleep apnea uses continues.^[10]

So a person whose only diagnosis is obesity has no route as of November 2026. Under federal law, any state may leave weight-loss drugs out of Medicaid, and the pilot was Utah’s exception to that.^[5] Our explainer on Medicaid and Ozempic or Wegovy covers the federal rules.

When will Utah Medicaid pay for Wegovy or Zepbound now?

For three uses, each limited to adults 18 and older and each requested on the same form.^[1] Every request starts with shared conditions: an exercise program and calorie-restricted diet in the chart, no medullary thyroid cancer or MEN2 in the patient or the family, no pregnancy, no second GLP-1, GIP or DPP-4 drug, and a plan to reach the minimum dose needed for renewal within six months.^[1]

Unlike some states, Utah’s form does not print a diabetes exclusion on these three routes.^[1] It does point anyone using Ozempic, Mounjaro or another diabetes GLP-1 to the drug list instead.^[1]

What does Utah require for Wegovy after a heart attack or stroke?

A BMI of at least 27 and a past heart attack, a coronary stent or bypass, a stroke, or symptomatic peripheral artery disease, shown by leg pain with an ankle-brachial index under 0.85, a revascularization or an amputation.^[1] The patient must also be on the usual secondary-prevention care.^[1] Listing stents and bypass surgery widens the route a little beyond a strict heart-attack history; the Wegovy label itself speaks of established cardiovascular disease with obesity or overweight.^[6]

The renewal test is concrete: after 20 weeks the patient must have lost at least 5% of baseline weight and kept it off, and must still be on secondary-prevention treatment.^[1] Our article on GLP-1s after a heart attack covers what the heart trial measured.

Does Utah Medicaid cover Zepbound for sleep apnea?

Yes, with conditions stricter than the label. A neurologist, pulmonologist, ear, nose and throat doctor or other sleep specialist must prescribe or consult. The patient needs a BMI of at least 30 and an AHI of 15 or more on an in-lab attended study or polysomnography, so a home sleep test may not be enough.^[1] The patient must also be using positive airway pressure at least 70% of the time and keep using it alongside Zepbound, unless they cannot tolerate it or the prescriber gives another reason.^[1]

Renewal needs the AHI to drop by at least 20%, or the apnea to reach remission or mild, symptom-free status.^[1] The Zepbound label covers moderate to severe sleep apnea in adults with obesity and sets no PAP condition.^[7] Our guide to Zepbound for sleep apnea covers the trials.

Will Utah Medicaid cover Wegovy for MASH?

Yes, for the injection only. A gastroenterologist, hepatologist or other liver specialist must prescribe or consult, and fibrosis must be stage F2 or F3 on two kinds of evidence: an age-adjusted FIB-4 score plus a biopsy, a vibration-controlled transient elastography scan, an ELF score or MR elastography.^[1] Decompensated cirrhosis, moderate to severe liver impairment and other liver diseases such as hepatitis or liver cancer all disqualify.^[1] To renew, the patient must be on the 2.4 mg dose, or 1.7 mg if the higher one is not tolerated, after 17 weeks, with chart notes showing a positive response.^[1] The FDA approved this use on an accelerated basis; our page on GLP-1s for MASH explains the evidence.^[6]

Does Utah Medicaid cover Ozempic and Mounjaro for diabetes?

Yes, and with less paperwork than the other routes. On the November 2026 fee-for-service list, Mounjaro, Ozempic injection, Trulicity and Victoza are preferred, and the prescriber writes a type 2 diabetes diagnosis code on the prescription rather than filing a prior authorization.^[2] Mounjaro, Trulicity and Victoza start at age 10 and Ozempic at 18.^[2] The list limits this class to type 2 diabetes and allows one GLP-1 a month.^[2] Rybelsus, the Ozempic tablet and the rest are non-preferred and need a coverage exception.^[2]

How do you appeal a Utah Medicaid denial?

Start with the denial reason. A missing in-lab sleep study, PAP record or second liver test is usually fixed by refiling with it; the fax for pharmacy requests is 855-828-4992.^[1] A request for weight loss alone has little to argue, because fee-for-service coverage for that use ended June 30, 2026.^[10]

Formal hearings are handled by the state health department’s hearings office, by form, email or mail to PO Box 143105, Salt Lake City, UT 84114-3105; its phone is 801-538-6576.^[4] Members of an accountable care organization must finish their plan’s appeal first.^[4] The state’s hearings page gives 90 days from the notice for eligibility and disability decisions but names no separate deadline for drug denials, so go by the date on your notice.^[4] Our guide to prior authorization and appeals covers the file, and the Utah state page has the Medicaid facts in brief.

What are the options for weight loss without Utah Medicaid?

Manufacturer copay cards do not help: Lilly’s Zepbound card terms exclude anyone in a government-funded program, Medicaid included.^[8] In the self-pay prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly charges $299 for Zepbound at the starting dose, $399 at 5 mg and $449 at 7.5 mg and up when each refill comes within 45 days.^[8][9] Our list of the cheapest ways to pay for a GLP-1 without insurance compares the options.